| Price | 1,582.00on 24-05-2019 at 16:30:00 |
|---|---|
| Change | 10.40 0.66% |
| Buy | 1,581.60 |
| Sell | 1,581.20 |
| Buy / Sell GSK Shares | |
| Last Trade: | Buy 76,133 at 1,582.00p |
| Day's Volume: | 5,548,070 |
| Last Close: | 1,571.60p |
| Open: | 1,577.60p |
| ISIN: | GB0009252882 |
| Day's Range | 1,570.60p - 1,586.80p |
| 52wk Range: | 1,408.80p - 1,648.80p |
| Market Capitalisation: | £78,246m |
| VWAP: | 0.00p |
| Shares in Issue: | 4,946m |
Recent Trades History Glaxosmithkline (GSK) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 76,133 | 1,582.00 | 17:11:59 - 24-May-19 | |
| Sell* | 217 | 1,572.357 | 18:28:17 - 24-May-19 | |
| Sell* | 524,972 | 1,579.523 | 17:44:40 - 24-May-19 | |
| Sell* | 111 | 1,579.438 | 17:16:05 - 24-May-19 | |
| Sell* | 814 | 1,572.434 | 17:10:48 - 24-May-19 | |
| Sell* | 32 | 1,572.356 | 17:10:04 - 24-May-19 | |
| Buy* | 589 | 1,581.902 | 17:06:32 - 24-May-19 | |
| Buy* | 47,115 | 1,581.840 | 17:06:32 - 24-May-19 | |
| Buy* | 1,196 | 1,581.91 | 17:06:32 - 24-May-19 | |
| Buy* | 6,423 | 1,581.890 | 17:06:32 - 24-May-19 | |
Share Price History for Glaxosmithkline |
|||||
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 24th May 2019 (Fri) | 1,577.60 | 1,586.80 | 1,570.60 | 1,571.60 | 5,548,070 |
| 23rd May 2019 (Thu) | 1,580.60 | 1,594.80 | 1,571.40 | 1,571.20 | 7,779,363 |
| 22nd May 2019 (Wed) | 1,547.00 | 1,571.20 | 1,543.40 | 1,544.60 | 11,438,188 |
| 21st May 2019 (Tue) | 1,551.80 | 1,558.60 | 1,539.20 | 0.00 | 5,887,779 |
| 20th May 2019 (Mon) | 1,554.00 | 1,557.00 | 1,538.40 | 1,555.00 | 4,157,633 |
| 17th May 2019 (Fri) | 1,544.00 | 1,557.80 | 1,536.80 | 1,550.00 | 20,150,479 |
| 16th May 2019 (Thu) | 1,525.80 | 1,550.00 | 1,517.20 | 1,534.00 | 6,042,109 |
| 15th May 2019 (Wed) | 1,520.60 | 1,539.00 | 1,518.20 | 1,516.60 | 7,235,156 |
| 14th May 2019 (Tue) | 1,519.20 | 1,527.40 | 1,513.60 | 1,512.40 | 4,482,478 |
| 13th May 2019 (Mon) | 1,508.60 | 1,513.80 | 1,495.40 | 1,502.00 | 5,598,127 |
| 10th May 2019 (Fri) | 1,520.80 | 1,527.60 | 1,498.00 | 1,518.20 | 5,536,677 |
| 9th May 2019 (Thu) | 1,520.00 | 1,531.20 | 1,511.60 | 1,524.40 | 5,786,903 |
| 8th May 2019 (Wed) | 1,515.00 | 1,532.80 | 1,506.80 | 1,517.80 | 5,790,681 |
| 7th May 2019 (Tue) | 1,545.00 | 1,551.40 | 1,514.20 | 1,552.20 | 10,924,240 |
| 6th May 2019 (Mon) | 0.00 | 0.00 | 0.00 | 0.00 | 0 |
| 3rd May 2019 (Fri) | 1,555.20 | 1,572.00 | 1,545.80 | 1,547.40 | 5,834,203 |
| 2nd May 2019 (Thu) | 1,585.00 | 1,585.00 | 1,545.80 | 1,559.80 | 6,520,441 |
| 1st May 2019 (Wed) | 1,575.20 | 1,598.00 | 1,532.00 | 1,573.40 | 11,132,618 |
| 30th Apr 2019 (Tue) | 1,569.00 | 1,582.60 | 1,557.40 | 1,569.20 | 7,003,022 |
| 29th Apr 2019 (Mon) | 1,567.20 | 1,573.20 | 1,554.20 | 1,561.40 | 4,764,105 |
| 26th Apr 2019 (Fri) | 1,563.80 | 1,569.00 | 1,552.40 | 1,555.20 | 7,831,873 |
GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.
If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.
On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.
News - Sunday, May 26, 2019
The head of emerging markets at GlaxoSmithKline, Abbas Hussain, has issued a statement admitting that employees had acted in breach of Chinese Law and stating that the company will review the way it operated in China, amidst a corruption and bribery scandal....
News - Sunday, May 26, 2019
The FTSE 100 closed up by 56.51 points, or 0.9 percent, on Tuesday, thanks to some positive activity in the pharmaceuticals sector. By the end of the trading session on Tuesday the FTSE 100 was up to 6,681.76, sitting at a two week high, and close to its closing peak for the year....
